The genetic spectrum of NF1 variants in 10 unrelated Chinese families with neurofibromatosis type 1

References

1. 1.↵
   1. Legius E,
   2. Messiaen L,
   3. Wolkenstein P,
   4. Pancza P,
   5. Avery RA,
   6. Berman Y, et al.

   Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 2021; 23: 1506-1513.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Tsipi M,
   2. Poulou M,
   3. Fylaktou I,
   4. Kosma K,
   5. Tsoutsou E,
   6. Pons MR, et al.

   Phenotypic expression of a spectrum of neurofibromatosis type 1 (NF1) mutations identified through NGS and MLPA. J Neurol Sci 2018; 395: 95-105.

   OpenUrlCrossRef
3. 3.↵
   1. Kerashvili N,
   2. Gutmann DH

   . The management of neurofibromatosis type 1 (NF1) in children and adolescents. Review Expert Rev Neurother 2024; 24: 409-420.

   OpenUrl
4. 4.↵
   1. Rana S,
   2. Low CE,
   3. Karthikeyan M,
   4. Jean Aan Koh M,
   5. Ngeow J,
   6. Chiang J

   . A systematic review of diagnostic modalities and strategies for the assessment of complications in adult patients with neurofibromatosis type 1. Cancers (Basel) 2024; 16: 1119.

   OpenUrl
5. 5.↵
   1. Wang D,
   2. Zhang BH,
   3. Wen X,
   4. Chen KH,
   5. Xiao HT,
   6. Xu XW, et al.

   Clinical features and surgical treatments of scoliosis in neurofibromatosis type 1: a systemic review and meta-analysis. Eur Spine J 2024; 10.1007/s00586-024-08194-w.
6. 6.↵
   1. Sarin KY,
   2. Bradshaw M,
   3. O’Mara C,
   4. Shahryari J,
   5. Kincaid J,
   6. Kempers S, et al.

   Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1. Sci Adv 2024; 10: eadk4946.

   OpenUrl
7. 7.↵
   1. Mo J,
   2. Moye SL,
   3. McKay Rm,
   4. Le LQ

   . Neurofibromin and suppression of tumorigenesis: Beyond the GAP. Oncogene 2022; 41: 1235-1251.

   OpenUrlCrossRef
8. 8.↵
   1. Mabyalwa Mudau M,
   2. Dillon B,
   3. Smal C,
   4. Feben C,
   5. Honey E,
   6. Carstens N, et al.

   Mutation analysis and clinical profile of South African patients with neurofibromatosis type 1 (NF1) phenotype. Front Genet 2024; 15: 1331278.

   OpenUrl
9. 9.↵
   1. Anastasaki C,
   2. Woo AS,
   3. Messiaen LM,
   4. Gutmann DH

   . Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning. Hum Mol Genet 2015; 24: 3518-3528.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Zhu B,
    2. Zheng T,
    3. Wang W,
    4. Gu Y,
    5. Wei C,
    6. Li Q, et al.

    Genotype-phenotype correlations of neurofibromatosis type 1: a cross-sectional study from a large Chinese cohort. J Neurol 2024; 271: 1893-1900.

    OpenUrl
11. 11.↵
    1. Han P,
    2. Wei G,
    3. Cai K,
    4. Xiang X,
    5. Deng WP,
    6. Li YB, et al.

    Identification and functional characterization of mutations in LPL gene causing severe hypertriglyceridaemia and acute pancreatitis. J Cell Mol Med 2020; 24: 1286-1299.

    OpenUrl
12. 12.↵
    1. Zhang R,
    2. Chen R,
    3. Han P,
    4. Chen F,
    5. Kuang S,
    6. Meng Z, et al.

    Whole exome sequencing identified a homozygous novel variant in CEP290 gene causes Meckel syndrome. J Cell Mol Med 2020; 24: 1906-1916.

    OpenUrl
13. 13.↵
    1. Ulusal SD,
    2. Gurkan H,
    3. Atli E,
    4. Ozal SA,
    5. Ciftdemir M,
    6. Tozkir H, et al.

    Genetic analyses of the NF1 gene in Turkish neurofibromatosis type I patients and definition of three novel variants. Balkan J Med Genet 2017; 20: 13-20.

    OpenUrl
14. 14.↵
    1. Jett K,
    2. Friedman JM

    . Clinical and genetic aspects of neurofibromatosis 1. Genet Med 2010; 12: 1-11.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Riva M,
    2. Martorana D,
    3. Uliana V,
    4. Caleffi E,
    5. Boschi E,
    6. Garavelli L, et al.

    Recurrent NF1 gene variants and their genotype/phenotype correlations in patients with Neurofibromatosis type I. Genes Chromosomes Cancer 2022; 61:10-21.

    OpenUrl
16. 16.↵
    1. Palma Milla C,
    2. Lezana Rosales JM,
    3. Lopez Montiel J,
    4. Andres Garrido LD,
    5. Sanchez Linares C,
    6. Carmona Tamajon S, et al

    : Neurofibromatosis type I: mutation spectrum of NF1 in spanish patients. Ann Hum Genet 2018; 82:425-436.

    OpenUrl
17. 17.↵
    1. Jang MA,
    2. Kim YE,
    3. Kim SK,
    4. Lee MK,
    5. Kim JW,
    6. Ki CS

    . Identification and characterization of NF1 splicing mutations in Korean patients with neurofibromatosis type 1. J Hum Genet 2016; 61: 705-709.

    OpenUrl
18. 18.↵
    1. Morbidoni V,
    2. Baschiera E,
    3. Forzan M,
    4. Fumini V,
    5. Ali DS,
    6. Giorgi G, et al.

    Hybrid minigene assay: An efficient tool to characterize mRNA splicing profiles of NF1 variants. Cancers (Basel) 2021; 13: 999.

    OpenUrl
19. 19.↵
    1. Zhang J,
    2. Tong H,
    3. Fu X,
    4. Zhang Y,
    5. Liu J,
    6. Cheng R, et al.

    Molecular characterization of NF1 and neurofibromatosis type 1 genotype-phenotype correlations in a Chinese population. Sci Rep 2015; 5: 11291.

    OpenUrl
20. 20.
    1. Banerjee S,
    2. Dai Y,
    3. Liang S,
    4. Chen H,
    5. Wang Y,
    6. Tang L, et al.

    A novel mutation in NF1 is associated with diverse intra-familial phenotypic variation and astrocytoma in a Chinese family. J Clin Neurosci 2016; 31: 182-184.

    OpenUrl
21. 21.
    1. Banerjee S,
    2. Lei D,
    3. Liang S,
    4. Yang L,
    5. Liu S,
    6. Wei Z, et al.

    Novel phenotypes of NF1 patients from unrelated Chinese families with tibial pseudarthrosis and anemia. Oncotarget 2017; 8: 39695-39702.

    OpenUrl
22. 22.↵
    1. Mao B,
    2. Chen S,
    3. Chen X,
    4. Yu X,
    5. Zhai X,
    6. Yang T, et al.

    Clinical characteristics and spectrum of NF1 mutations in 12 unrelated Chinese families with neurofibromatosis type 1. BMC Med Genet 2018; 19: 101.

    OpenUrl
23. 23.↵
    1. Wang W,
    2. Qin W,
    3. Ge H,
    4. Kong X,
    5. Xie C,
    6. Tang Y, et al.

    Clinical and molecular characteristics of thirty NF1 variants in Chinese patients with neurofibromatosis type 1. Mol Biol Rep 2019; 46: 4349-4359.

    OpenUrl
24. 24.↵
    1. Schubbert S,
    2. Shannon K,
    3. Bollag G

    . Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Stella A,
    2. Lastella P,
    3. Viggiano L,
    4. Bagnulo R,
    5. Resta N

    . Clinical presentation and genetic analyses of neurofibromatosis type 1 in independent patients with monoallelic double de novo closely spaced mutations in the NF1 gene. Hum Mut 2022; 43: 1354-1360.

    OpenUrl
26. 26.↵
    1. Xiao H,
    2. Yuan L,
    3. Xu H,
    4. Yang Z,
    5. Huang F,
    6. Song Z, et al.

    Novel and recurring disease-causing NF1 variants in two Chinese families with neurofibromatosis type 1. J Mol Neurosci 2018; 65: 557-563.

    OpenUrl
27. 27.↵
    1. Cichowski K,
    2. Jacks T

    . NF1 tumor suppressor gene function: narrowing the GAP. Cell 2001; 104: 593-604.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.
    1. Pemov A,
    2. Sung H,
    3. Hyland PL,
    4. Sloan JL,
    5. Ruppert SL,
    6. Baldwin AM, et al.

    Genetic modifiers of neurofibromatosis type 1-associated cafe-au-lait macule count identified using multi-platform analysis. PLoS Genet 2014; 10:e1004575.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Rojnueangnit K,
    2. Xie J,
    3. Gomes A,
    4. Sharp A,
    5. Callens T,
    6. Chen Y, et al.

    High incidence of Noonan syndrome features including short stature and pulmonic stenosis in patients carrying NF1 missense mutations affecting p.Arg1809: Genotype-phenotype correlation. Hum Mut 2015; 36: 1052-1063.

    OpenUrlCrossRefPubMed